Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2019-03-01 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
LYNPARZA RECEIVES POSITIVE EU CHMP OPINION
Regulatory Filings
2019-03-01 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is explicitly labeled with an 'RNS Number' and contains a notification dated March 1, 2019, regarding 'Voting Rights and Capital'. It states the total number of voting rights based on the issued share capital as of February 28, 2019, referencing the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This content directly relates to shareholder voting rights and capital structure notifications, which aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is distributed via RNS, the specific content is DVA, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains the actual required data, not just an announcement that a report is available.
2019-03-01 English
Lynparza receives positive EU CHMP opinion
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 6338R' and concludes with information about RNS, stating, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This strongly indicates a regulatory announcement disseminated via the RNS system. The content itself is a press release announcing a positive opinion from the EU CHMP regarding the drug Lynparza. Since this is a specific, time-sensitive regulatory announcement that doesn't fit neatly into the defined categories like ER (Earnings Release) or CT (Call Transcript), and it is distributed via the official regulatory news service (RNS), the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (12310 chars), but its primary function is the dissemination of a regulatory/market-moving update via the RNS channel.
2019-03-01 English
LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION
Regulatory Filings
2019-02-26 English
Lynparza significantly delayed disease progression
Earnings Release Classification · 99% confidence The document begins with 'RNS Number : 1143R' and concludes with information about RNS, stating it is 'the news service of the London Stock Exchange' and an 'approved Primary Information Provider'. The content itself is a press release announcing positive Phase III trial results for a drug (Lynparza) and includes quotes from executives and detailed background information. This format—a formal announcement disseminated via the Regulatory News Service (RNS)—is characteristic of a general regulatory announcement that doesn't fit the more specific categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). Since it is a formal regulatory announcement distributed through the official channel, the most appropriate classification is Regulatory Filings (RNS). The document length (9972 chars) is substantial, but the key identifier is the RNS header/footer. FY 2019
2019-02-26 English
BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT
Regulatory Filings
2019-02-25 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.